Compare Salesforce Inc (CRM) vs Ginkgo Bioworks Holdings Inc (DNA) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Salesforce Inc vs Ginkgo Bioworks Holdings Inc — how do they compare? Salesforce Inc trades at $168.3 (market cap $137.23B), while Ginkgo Bioworks Holdings Inc trades at $9.06 (market cap $590.53M). The key difference: Salesforce Inc is far larger — about 232.4× Ginkgo Bioworks Holdings Inc's market cap, and Salesforce Inc pays a 1.05% dividend while Ginkgo Bioworks Holdings Inc pays none. Which is the better fit depends on your goals.
| CRM | DNA | |
|---|---|---|
Market Cap | $137.23B | $590.53M |
Sector | Technology | Health |
52-Week High | $270.25 | $16.14 |
52-Week Low | $150.12 | $5.48 |
Enterprise Value | $167.28B | $627.78M |
Dividend Yield | 1.05% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Salesforce (CRM) trades at $171.22, up 4.84% today, but remains down significantly year-to-date amid a broader software sell-off. The company demonstrates strong fundamentals with revenue growth to $37.90B in 2025 and a net income margin of 18.73%. Recent quarters show consistent earnings beats, and analyst consensus remains strongly bullish with a $235.90 price target. Technical indicators are mixed, with the stock near key support at $167.
The outlook is positive for long-term investors given robust profitability, AI-driven growth initiatives, and a discounted valuation. Key risks include intense competition in the SaaS sector and macroeconomic sensitivity. The current price presents a potential entry point relative to analyst targets, but volatility may persist in the near term.
DNA trades at $9.05, down 0.44% on the day, reflecting ongoing investor caution. The technical outlook is bearish, while fundamentals show significant losses with a net income margin of -201.05% and negative cash flows. Recent earnings have been mixed, missing estimates in two of the last three quarters. Analyst sentiment is divided, with a slight lean toward buy ratings amid high volatility and operational challenges.
The outlook remains challenging due to persistent losses and cash burn, though analyst coverage suggests potential long-term value. Key risks include execution missteps and intense competition in biotechnology. Investment appeal hinges on future profitability improvements and successful business model execution.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Salesforce Inc
Salesforce Inc provides enterprise cloud computing solutions. The company offers customer relationship management technology that brings companies and customers together. Its Customer 360 platform helps the group to deliver a single source of truth, connecting customer data across systems, apps, and devices to help companies sell, service, market, and conduct commerce. It also offers Service Cloud for customer support, Marketing Cloud for digital marketing campaigns, Commerce Cloud as an e-commerce engine, the Salesforce Platform, which allows enterprises to build applications, and other solutions, such as MuleSoft for data integration.
Read more on CRM →About Ginkgo Bioworks Holdings Inc
Ginkgo Bioworks is a leading horizontal platform for cell programming. It uses advanced automation and software to design custom organisms for customers across diverse industries, including food, agriculture, and pharma.
Read more on DNA →
